FDA: Antiemetic Shortage Announced
Emend 40mg, 80mg, and 125mg capsules are currently on backorder due to an increase in demand for the drug. An intermittent supply will be available in July in August for some products and it is anticipated that the backorder will be fully resolved in September. Emend for injection remains available.
Emend is a substance P/Neurokinin-1 (NK1) receptor antagonist approved for use in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin; and for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
For more information call (855) 543-3784 or visit FDA.gov.